Alectinib, an orally available drug, was first approved in 2015 by the US Food and Drug Administration (FDA)11 for Genentech and then by the European Medicines Agency (EMA) for Roche Pharmaceuticals12, with an indication as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC).13 The gene discussed is ALK; the disease is non-small cell lung carcinoma.